As of 2025-07-08, the Fair Value of Lineage Cell Therapeutics Inc (LCTX) is -0.35 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.95 USD, the upside of Lineage Cell Therapeutics Inc is -137.34%.
With the market price of 0.95 USD and our fair value calculation, Lineage Cell Therapeutics Inc (LCTX) is not a good investment. Investing in LCTX stocks now will result in a potential loss of 137.34%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -20.65 | -43.02 | -26.27 | -21.49 | -18.61 | -26.01 |
| YoY growth | -76.35% | -108.33% | 38.94% | 18.21% | 13.39% | -22.83% |
| Market Cap (mil) | 217.03 |
| P/E | |
| Forward P/E |
| EPS | -0.07 |
| Avg earnings growth rate | -22.83% |
| TTM earnings | -16.21 |